Novartis' TREM2 drug fails Phase 2 ALS trial
Novartis has scrapped development of a Phase 2 treatment candidate for amyotrophic lateral sclerosis, Endpoints News has learned. The Swiss pharma giant is ending work on VHB937/lifonebart in ALS, according to a
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease endpoints.news
- Skyhawk racks up more support for Huntington’s drug biopharmadive.com
